Quadrivalent Seasonal Influenza Vaccine Expands in China
Clover Biopharmaceuticals, Ltd. today announced that it had established a commercial partnership with Keyuan Xinhai Medical Products Trading Co. Ltd. as it prepares for the commercial launch of AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China.
“We are thrilled to partner with Kyuan Trade, which has a large and talented commercial team, a broad distribution network that extends across 31 provinces, municipalities, and autonomous regions, and an excellent modern logistics network,” said Joshua Liang, Chief Executive Officer, and Executive Director of Clover, in a press release on May 23, 2023.
Clover expects to launch AdimFlu-S (QIS) later in 2023.
China's seasonal influenza vaccine market has been growing by approximately 30% annually.
Moreover, demand in China continues to shift from trivalent to quadrivalent seasonal influenza vaccine options, which accounted for the majority of doses (70%) in 20222.
The WHO published Influenza Update N° 445 on May 15, 2023, stating:
- In Central Asia, no influenza detections were reported during this period despite continued testing.
- In Western Asia, influenza activity remained low overall, with detections of all seasonal influenza subtypes.
- In East Asia, influenza activity decreased overall, although detections of mainly influenza A(H1N1)pdm09 continued to increase in Hong Kong Special Administrative Region, China.
- A slight increase in influenza detections was reported in the Republic of Korea.
Flu shot news of the 2023-2024 influenza season is posted by Precision Vaccinations.